ABT vs. MDGL: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABT and MDGL, comparing key factors like performance, valuation metrics, dividends, and financial strength.
Company Overview
ABT’s market capitalization of 233.03 billion USD is substantially larger than MDGL’s 6.09 billion USD, indicating a significant difference in their market valuations.
ABT has a positive beta (0.74), indicating it generally moves with the broader market, whereas MDGL has a negative beta (-1.08), often moving inversely, which can offer diversification or hedging benefits.
Symbol | ABT | MDGL |
---|---|---|
Company Name | Abbott Laboratories | Madrigal Pharmaceuticals, Inc. |
Country | US | US |
Sector | Healthcare | Healthcare |
Industry | Medical - Devices | Biotechnology |
CEO | Mr. Robert B. Ford | Mr. William J. Sibold |
Price | 133.94 USD | 274.1 USD |
Market Cap | 233.03 billion USD | 6.09 billion USD |
Beta | 0.74 | -1.08 |
Exchange | NYSE | NASDAQ |
IPO Date | March 17, 1980 | February 6, 2007 |
ADR | No | No |
Performance Comparison
This chart compares the performance of ABT and MDGL over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
- ABT: $12699.35 (26.99%)
- MDGL: $11217.97 (12.18%)
Valuation Metrics Comparison
This section compares the market valuation of ABT and MDGL. Key takeaways regarding their valuation, when viewed within their industry context, are presented in the commentary that follows.
- MDGL’s Price-to-Earnings (P/E) ratio of -15.46 is negative. This indicates the company is currently not generating profit, a key factor that can weigh on its stock valuation and investor sentiment.
- MDGL’s Forward PEG ratio of -0.83 is negative. Such a figure commonly arises from negative earnings or forecasts of diminishing profitability, making standard valuation comparisons based on growth particularly challenging.
Symbol | ABT | MDGL |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | 17.33 | -15.46 |
Forward PEG Ratio (TTM) | 1.74 | -0.83 |
Price-to-Sales Ratio (P/S, TTM) | 5.50 | 19.18 |
Price-to-Book Ratio (P/B, TTM) | 4.79 | 8.52 |
EV-to-EBITDA (TTM) | 21.41 | -16.01 |
EV-to-Sales (TTM) | 5.66 | 18.97 |
Dividend Comparison
ABT provides a 1.70% dividend yield, potentially offering a blend of income and growth, whereas MDGL currently does not pay a dividend, possibly retaining profits to fund operations or growth initiatives.
Symbol | ABT | MDGL |
---|---|---|
Dividend Yield (TTM) | 1.70% | 0.00% |
Financial Strength Metrics Comparison
This section evaluates the financial strength of ABT and MDGL. Noteworthy observations on their financial resilience, considered from an industry perspective, are detailed in the points that follow.
- MDGL’s Interest Coverage Ratio (ICR) of -30.09 is negative. This signals that its current operating earnings are insufficient to meet its interest obligations, a critical red flag for its financial health and capacity to manage its debt.
Symbol | ABT | MDGL |
---|---|---|
Current Ratio (TTM) | 1.78 | 5.91 |
Quick Ratio (TTM) | 1.27 | 5.58 |
Debt-to-Equity Ratio (TTM) | 0.27 | 0.17 |
Debt-to-Asset Ratio (TTM) | 0.16 | 0.12 |
Net Debt-to-EBITDA Ratio (TTM) | 0.60 | 0.17 |
Interest Coverage Ratio (TTM) | 15.39 | -30.09 |